GeoVax Initiates Phase 3 Execution Activities for GEO-MVA Under EMA-Aligned Immunobridging PathwaySearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
GeoVax Initiates Phase 3 Execution Activities for GEO-MVA Under EMA-Aligned Immunobridging PathwayCompany Advances to Active Clinical Execution, Supporting Potential Accelerated Path Toward Regulatory Authorization
GeoVax Advances Gedeptin(R) Toward Phase 2 Initiation and Strategic Partnership OpportunitiesSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
GeoVax Advances Gedeptin(R) Toward Phase 2 Initiation and Strategic Partnership OpportunitiesNear-Term Clinical Milestones and Combination Strategy Position Program for Next Stage of Value Creation
GeoVax Highlights Gedeptin(R) as a Potential Immune-Sensitizing Platform Amid Rising Industry Investment in In Vivo Cancer TherapiesSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
GeoVax Highlights Single-Dose Mpox Vaccine Data at World Vaccine Congress 2026MVA-X Platform Demonstrates Single-Dose Durable Protection Comparable to Two-Dose Regimen
GeoVax Highlights Single-Dose Mpox Vaccine Data at World Vaccine Congress 2026MVA-X Platform Demonstrates Single-Dose Durable Protection Comparable to Two-Dose Regimen
GeoVax Provides Update on GEO-MVA ProgramClinical Product Release Testing Completed in Support of Pivotal Phase 3 Trial
GeoVax Reports 2025 Year-End Financial Results and Provides Business UpdateSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
GeoVax Positions GEO-MVA to Address Supply Constraints in Global Mpox and Smallpox Vaccine MarketSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
GeoVax Positions GEO-MVA to Address Supply Constraints in Global Mpox and Smallpox Vaccine MarketHighlights Critical Need for Additional MVA Vaccine Supply, Ending the Current Monopoly, Increasing Access and Supply Worldwide
GeoVax Initiates Outreach Regarding Future Procurement of GEO-MVA Mpox/Smallpox VaccineProgram Reaches Strategic Inflection Point as GEO-MVA Advances Toward Pivotal Phase 3 Study
GeoVax Announces a Warrant Inducement TransactionSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
GeoVax Announces a Warrant Inducement TransactionATLANTA, GA - March 31, 2026 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies against infectious diseases and cancer, today announced its entry into a warrant inducement agreement with existing healthcare-focused institutional investors of the Company for the immediate exercise of existing warrants (the "Existing Warrants") to purchase up to 634,658 shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”) at a reduced exercise price of $1.36 for gross cash proceeds of approximately $863,000, before deducting financial advisor fees and other transaction expenses. The Company intends to use the net proceeds from the offering for working capital and other general corporate purposes.
GeoVax Provides Update on GEO-MVA ProgramSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
GeoVax Announces European Society of Medicine Publication Highlighting GEO-CM04S1 as a Next-Generation COVID-19 Vaccine for Immunocompromised Patients Peer-Reviewed Article Describes Clinical and Immunologic Rationale for Dual-Antigen MVA-Based Vaccine Designed to Address Limitations of First-Generation COVID-19 Vaccines in Highly Vulnerable Populations
GeoVax Initiates Outreach Regarding Future Procurement of GEO-MVA Mpox/Smallpox VaccineSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
GeoVax Announces Oncology Advisory Board to Advance Gedeptin(R) Development Across Solid TumorsSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
GeoVax Announces Oncology Advisory Board to Advance Gedeptin(R) Development Across Solid TumorsMembers Bring Deep Expertise in Immuno-Oncology, Translational Medicine, and Checkpoint Inhibitor Combination Strategies
GeoVax Secures Exclusive License for Gedeptin(R) + Immune Checkpoint Inhibitor Combination TechnologyLicense Strengthens GeoVax’s Immuno-Oncology Strategy and Expands Intellectual Property Foundation for Combination Therapies Across Solid Tumors
GeoVax Secures Exclusive License for Gedeptin(R) + Immune Checkpoint Inhibitor Combination TechnologySearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
GeoVax Endorses Global Call to Sustain Mpox Response as Evidence Confirms Epidemic Is Far From OverSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
